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Abstract
Recently, whole-genome sequencing, especially exome sequencing, has successfully led to the identification of causal
mutations for rare monogenic Mendelian diseases. However, it is unclear whether this approach can be generalized and
effectively applied to other Mendelian diseases with high locus heterogeneity. Moreover, the current exome sequencing
approach has limitations such as false positive and false negative rates of mutation detection due to sequencing errors and
other artifacts, but the impact of these limitations on experimental design has not been systematically analyzed. To address
these questions, we present a statistical modeling framework to calculate the power, the probability of identifying truly
disease-causing genes, under various inheritance models and experimental conditions, providing guidance for both proper
experimental design and data analysis. Based on our model, we found that the exome sequencing approach is well-
powered for mutation detection in recessive, but not dominant, Mendelian diseases with high locus heterogeneity. A
disease gene responsible for as low as 5% of the disease population can be readily identified by sequencing just 200
unrelated patients. Based on these results, for identifying rare Mendelian disease genes, we propose that a viable approach
is to combine, sequence, and analyze patients with the same disease together, leveraging the statistical framework
presented in this work.
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Introduction
One of the major gaps in our understanding of human genetic
diseases is to fully categorize their molecular basis. To date, the
underlying mutations for at least 3000 human disease loci
remain to be determined (http://www.ncbi.nlm.nih.gov/Omim/
mimstats.html). Recent developments in high throughput sequenc-
ing technologies provide an opportunity for accelerating the
disease gene identification process. In the past two years exome
sequencing, an economical alternative approach to whole genome
sequencing, has achieved ground-breaking success in identifying
genes associated with rare monogenic Mendelian diseases
(RMMDs). In these studies, a number of unrelated patients with
the same rare genetic disease were exome-sequenced to identify
coding variants [1,2].
Ng et al. [2] were the first to demonstrate the effectiveness of this
approach: by sequencing the exomes of four patients of the Miller
syndrome from three kindreds, they identified the gene DHODH as
the sole candidate. Subsequently, exome sequencing has been
successfully applied to several rare Mendelian disorders with a
monogenic component [3,4,5,6,7,8,9,10,11,12,13]. While most of
these cases were recessive diseases[1,2,4,5,6,7,8,9,11,12,13], this
approach can be also applied to dominant diseases [3,10], albeit
substantially more complex bioinformatics analyses are required.
Family history data are extremely helpful as they can narrow down
the scope of search for disease mutations from genome-wide to co-
segregation or identical-by-descent regions [4,5,6,7,10,11,12,14,15].
While exome sequencing has been widely used due to its relatively
low cost and clear interpretation of identified changes, whole
genome sequencing has been used to identify both coding and non-
coding mutations [14,15,16].
It is noted [17] that the exome sequencing for rare monogenic
Mendelian diseases (exome-RMMD) and that of exome sequencing
for complex traits (exome-GWAS) are two distinctive experimental
designs that applied to diseases with different genetic architectures:
While exome-RMMD assumes that rare Mendelian diseases are
caused by rare genetic variants with complete or very high
penetrance, exome-GWAS design does not assume that complex
traits are caused by rare variants nor complete penetrance. As a
result, exome-RMMD and exome-GWAS engage largely different
analysis approaches [17]. There have been enthusiasms and
preliminary studies regarding exome-GWAS, and some works
[18,19] exist for the statistical guidance and power considerations
for exome-GWAS, there has been a lack of statistical framework for
exome-RMMD.Thiswork isfocusedonly on Mendeliandiseases or
complex diseases that transmit in a Mendelian fashion in families.
Notably the exome-RMMD design may apply to a disease cohort
with a large number of unrelated individuals (e.g., n=500–1000)
with a high degree of locus heterogeneity, which resembles classical
whole-genome association studies for complex traits. The main
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of the cohort but rather on the underlying genetic architecture,
although exome-RMMD typically requires a smaller sample size.
Despite these successes on exome sequencing approach for rare
mendelian diseases, concerns remain regarding the feasibility of
extending this approach to Mendelian diseases more broadly.
First, there is a concern on publication bias. Some successful
publications on using very small number of families to find
causative genes for Mendelian diseases may not indicate that all
rare Mendelien diseases can be solved this way. We are aware that
many studies suffer from uncertainty and limited power to trim
down the final candidate gene list. Therefore, a statistical modeling
framework is needed for the guidance for study design and data
analysis.
Specifically, there is a concern on factors that can negatively
impact the utility of this approach. First, limitations of exome
capture sequencing technology result in both false negatives and
false positives in mutation detection. In the case of false negatives,
pathogenic variants may not be detected in any given sample due
to insufficient sequence coverage of some exonic and non-exonic
regions. In contrast, false positives resulting from both short read
mapping and sequencing errors are commonly observed with
current sequencing technologies. Second, distinguishing causative
mutations from other non-causative rare variants in patients is
often not straightforward. Each individual harbors hundreds of
rare and private variants [20]. Our ability to predict the functional
significance of these rare variants is still very limited. Third, most
Mendelian diseases are highly heterogeneous at both the clinical and
the molecular levels. Most genetic diseases are locus-heterogeneous
as mutations in any one of many genes can cause similar clinical
phenotypes. Often mutations in a single gene account for only a
small portion of the patients (,10%). In such cases, simply
intersecting candidate genes derived from sequencing of several
patients is unlikely to lead to identification of disease genes. It is
essential, therefore, to systematically evaluate the impact of these
factors on the statistical power of disease gene identification by
exome sequencing in order to evaluate and guide experimental
design.
In this report, we present a formal analytical framework for
exome sequencing studies for RMMDs. Our framework estab-
lishes a quantitative link between the statistical power and various
disease and experimental variables. Based on our model, we found
that underlying mutations and genes can be reliably identified by
sequencing a moderate number of patients for recessive RMMDs
with substantial locus heterogeneity. In contrast, a greater number
of patients or additional genetic mapping data is needed for
mapping genes of dominant RMMDs. Validated by computer
simulationsand real data,a web analytic tool has beenimplemented
which can be used as a guide for both experimental design and data
analysis. Based on our results, we confirmed that a viable approach
for identifying RMMD disease genes is to combine patients with the
same clinical disease and to perform exome sequencing and
subsequent analysis together. Moreover, this approach may be
applicable to disease cohorts with extensive genetic heterogeneity,
leveraging the statistical framework presented in this work.
Results
Modeling framework
As listed in Table 1, we identified a list of relevant experimental
and disease factors which are likely to impact experimental results.
A typical exome-sequencing study for a rare Mendelian disease
consists of a number of unrelated patients (denoted by n). DNA
samples of these individuals are subjected to exome capture and
sequencing. The number of genes (denoted by M) covered by the
exome capture procedure varies depending on the capture design.
Obviously causative genes missed by the capture procedure cannot
be identified by this approach and account for upfront power loss
regardless of downstream filtering and statistical analysis. Our
framework is thus purely focused on the statistical power within the
captured region and the overall power of the exome sequencing
experiment should be actually smaller. For each sample, a
preliminary list of putative variants identified by sequencing will be
subject tofiltering proceduressuchasexcludingcommonvariantsin
the human population, low quality variants, and synonymous
changes, resulting in m candidate mutations. In cases where genetic
mapping information is available, variants mapped outside of
disease loci identified by homozygosity mapping [5,6] or linkage
analyses [15] can also be excluded, resulting in a shorter list of
candidate mutations. These m variants would include zero or one
disease-causing mutation(s) while the rest are rare or private non-
causative mutations and thus serve as a measure of level of false
positives. The probability that a disease-causing mutation is present
in the final list of m variants is denoted as the sensitivity of mutation
detection, Ps. Whilethepresentwork focuses onthestatistical power
assuming the m and Ps are given, an important decision faced by
investigators is to choose a proper filtering procedure: a more
stringent filtering would reduce false positive (smaller m), but at the
same time reducing the power of detecting the true disease-causing
mutations (smaller Ps). The complex relationship between m and Ps,
depending on the details of filtering and the nature of the disease, is
out of the scope of the present work.
Table 1. Experimental design and disease factors of the causative gene relevant to the statistical power of exome sequencing for
RMMDs.
Factor Symbol Type Definition
Impact to power when other
factors held constant
Sample size n Design Number of unrelated patients sequenced increase
Locus heterogeneity R Disease Proportion of sequenced patients responsible decrease
Dominant/Recessive Disease Genetic link of gene to disease. Dominant=1, recessive=0 decrease
Relative gene length w Disease Ratio of the length of the gene to the average gene length decrease
Sensitivity of detecting
mutations
Ps Design Probability of a true mutation in the captured region being
identified after filtering
increase
Filtering efficiency m Design Number of mutations identified after filtering decrease
Genome size M Design Total number of genes in the captured region decrease
doi:10.1371/journal.pone.0031358.t001
Statistical Power of Exome Sequencing
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design, execution, and subsequent data analysis, other factors that
are intrinsic to the underlying disease also need to be considered.
Three intrinsic factors have been identified, including the mode of
inheritance (dominant or recessive), the fraction of sequenced
patients for which a given gene is responsible (denoted by R), and
the conditional probability that a random mutation falls in the
gene, given that there is a mutation. The latter is proportional to
the gene length, referring to the total lengths of the exons of a
gene, and the background mutation rate in the gene region. For
the sake of simplicity, we use the relative gene length (denoted by
w), defined as the ratio between the candidate gene size to the
average gene size in the genome, to incorporate the probability
of having a random mutation in the gene, recognizing that a
complete treatment would also incorporate the background
mutation rate information.
As will be detailed in the Materials and Methods section, we
examined three test statistics at the gene-level, including Ta, Tr,a n d
Td. For a gene, the basic test statistic is the total variant count
among all sequenced patients. This statistic is denoted as Ta since it
is extended from an additive model. For a recessive model, Ng et al
[2] used the filter requiring at least two mutations in the gene. This
motivates us to define the recessive version of the statistic, Tr, as the
count of patients with at least two mutations in the gene.
Analogously, we denote the count of patients with any number of
mutations in a gene, or the collapsed count, as Td, the dominant
version of the statistic. We assume that mutations occur in a gene
randomly with a probability proportional to w, the relative
gene length. We further assume that different mutations occur
independently, i.e., there is no linkage disequilibrium between these
rare mutations. It can be derived, with a tight approximation, that
each of these statistics Ta, Tr,a n dTd follows a different binomial
distribution under the null hypothesis where there is no association
between the gene and the disease. The parameters of the binomial
distribution are determined by n, w, m,a n dM. Based on these
binomial distributions, it is appropriate to conduct exact binomial
tests and the type-I error rate and significance-level cutoff can be
determined. The p-values are subject to Bonferroni correction
controlling for the fact that a total of M hypotheses, one for each
gene, are being tested genome-wide. Upon multi-testing correction,
results obtained from theoretical calculations are consistent with
those obtained from computer simulations (Table S1).
As will be detailed described in the Materials and Methods
section, given the null distribution, the power of a binomial test
can be derived for all three statistics, Ta, Tr, and Td. Our
derivations are based on the following realistic assumptions. First,
we assume that in the recessive case exactly two causal mutations
after filtering per individual are present in the gene. This is
plausible as individuals with homozygous or compound heterozy-
gous mutations would incur severe damage to their fitness and thus
unlikely to produce offsprings with additional mutations. Similarly,
we assume that in the dominant case exactly one causal mutation
after filtering is present in one copy of a gene per individual. Based
on these assumptions, it can be derived that each of the statistics
Ta, Tr and Td, follow a different binomial distribution, with a
higher mean than the null distribution, except that under the
recessive model Ta follows a distribution closely resembling
binomial. Based on this analytical framework, the effect of all
factors listed in Table 1 on the experiment can be systematically
evaluated by theoretical power calculations, with all calculated
results being validated by computer simulations (data not shown).
We remark that all proposed test statistics, Ta, Tr and Td are
different from many test statistics proposed from rare variant
association (as reviewed by several papers including [17,21,22]).
Primarily, the proposed methods are ‘‘case-only’’ statistics since
exome-RMMD is a case-only design and individuals’ phenotypes
are largely ignored, this is fundamentally different from rare
variant association methods whose very goal is to identify the
statistical association between individuals’ genotypes and pheno-
types. For example, even though the Ta statistic resembles the
simple sum test statistic [23] and the Td statistic resembles the
collapsing method [24], these rare variant association methods
only combine the information across multiple variants in a region
for an individual, while the proposed methods further collapse
individual-level statistics into a single statistic.
All factors directly impact the power of mutation
detection
The statistical power of exome sequencing for rare monogenic
Mendelian disease is high for genes with a recessive link (versus a
dominant link) to the underlying disease, with a low genetic
heterogeneity (1/R), or of a short length (w) (Figure 1). Moreover,
high filtering efficiency (1/m), large sample size (n), and high
sensitivity of mutation detection (Ps, data not shown) can boost the
power further. In a near optimal combination, R=1,Ps=0.9, and
m=5, even a sample size of two almost guarantees identification of
the gene. Below we discuss in detail the effect of individual
parameters while fixing the remaining parameters to the following
default values: R=0.05, w=1,Ps=0.8, m=300, and M=20,000.
The justifications for these choices are given below in the
discussion of individual factors.
Genes underlying highly heterogeneous diseases can be
identified by sequencing a moderate number of patients
Most Mendelian diseases are genetically heterogeneous and quite
often mutations in one gene account for only a small fraction of
patients in a sample collection. To evaluate the impact of heterogeneity
on the power to identify disease genes, we vary the fraction of cases
caused by mutation in the same gene, R,f r o m0 . 0 1t o1 .
Under a recessive model, power is high with either large sample
sizes or low genetic heterogeneities (Figure 2, upper panel). For
example, when R=1, just two patients will already render a power
of 0.41 for Tr. When R=0.2, power of Tr is high (.0.8) for n=40.
At very low R values, e.g., R=0.05, sample size must be large
(n=200) to achieve sufficient power. At the extremely low values
of R (e.g., 0.01), one would not expect to map a gene with n=100
samples, because the expected value of Tr equals one. However it
is remarkable that n=1000 is sufficient to maintain a modest
power (.0.5).
The sensitivity of detecting causative mutations by exome
sequencing, Ps, is also an important factor. When taking Ps to the
default value of 0.8, in some cases (Figure 2, middle panel), the
additive version of the T-statistic Ta, instead of the recessive
version of the T-statistic Tr, can be used to identify genes that are
enriched for rare changes. For large R values (i.e., R$0.1) at small
sample sizes, Ta actually can have a higher power than Tr. Tr is
more powerful for R#0.1. The reason for this counterintuitive
behavior of Tr and Ta is the following: Imperfect sensitivity of
mutation detection (e.g., Ps=0.8) always results in some power
loss. For a causal gene with two true mutations, there is a chance
that only one mutation is not detected in an individual. While Tr
will lose one count from this individual, Ta can still collect one
count from this individual and thus the loss of power for Ta might
be smaller. Indeed, when sensitivity of detecting mutations is
perfect (Ps=1), Tr is universally more powerful than Ta. In any
case, Tr universally has better power to detect mutation than Td
for recessive data (Figure S1).
Statistical Power of Exome Sequencing
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criteria for calling a gene positive in an individual are different
from that of recessive diseases, and the power for identifying
causative genes in dominant diseases is substantially lower than
that of recessive diseases. The power of detecting dominant disease
genes at various R levels is calculated and shown in Figure 2, lower
panel. Under a dominant model, power can be good for modest
sample sizes, when R is sufficiently large. For example, when
R=0.5, power is good (.0.8) for n=20. When R=0.2, power is
good (.0.8) for n=70. At very low R values, e.g., R=0.05, even a
very large sample size (e.g., n=1000) can only offer a power of
0.76. When R,0.05, no sample size smaller than 1000 would be
sufficient.
High sensitivity of detecting mutations is required to
identify disease genes
Sensitivity of detecting mutations in an individual is mainly
affected by three factors: the coverage of the capture technology,
the sequencing quality, and the read mapping quality. Various
capture methods have been developed to enrich the coverage of
human exons. Unfortunately, none of the current methods can
capture all exons and typically 10–15% of exons remaining poorly
covered. Since the ceiling of coverage is often beyond investiga-
tors’ control, we define the sensitivity of detecting mutations Ps as
the probability of detecting a mutation within the scope of exon
capture technology. Fortunately, with the advancements of next-
generation and possibly third-generation sequencing technologies,
higher sequence coverage and low sequencing error rates can be
achieved at an affordable cost. For heterozygous sites, it has been
estimated that about 206 coverage is required to reliably detect
both alleles. Still, it is well known that the sequencing coverage and
read mappability is not uniform across the genome and thus Ps
would fluctuate from gene to gene and within a gene. Mutations at
certain nucleotide positions may be difficult to detect for any
patient sequenced. Therefore, although an overall 97% sequenc-
ing coverage of the captured region is reported with current
technology [2], we take a somewhat conservative value Ps=0.8 in
our discussion. Sufficient sensitivity of detecting mutations
(Ps.0.7) is required to achieve an adequate power even when
sample size is large (Figure 3). In practice, maintaining Ps$0.9 is
reasonably affordable and is sufficient to attain the desired power.
Moreover, extremely high coverage does not yield a good return
on investment.
Strict filtering of false positives has limited impact on
mapping recessive disease genes but can dramatically
improve the power of mapping dominant disease genes
The advantage of exome sequencing for RMMDs is that, based
on the assumption that the disease is caused by rare variants,
common variants can be safely filtered out using existing SNP
databases, and typically only about a few hundred mutations (m)
would remain in an individual. For reference, counting new (not
in dbSNP129, 1000 genomes, nor control exomes) NS/SS/I
(nonsynonymous, splice site, and short coding indel) variants per
patient, Ng et al identified m=526 in their four patients Miller
syndrome sample [2], and about m=694 (Table 1 of Ng, et al. [3])
in their 10 patients Kabuki syndrome sample [3]. Using a more
strict loss-of-function filter, they identified m=75 for the latter
study [3]. Noting that m can be reduced further if additional
linkage mapping information is considered, we set the default
Figure 1. The calculated power of exome sequencing for rare monogenic Mendelian diseases for various parameter combinations.
doi:10.1371/journal.pone.0031358.g001
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disease genes for the range from m=5tom=500.
Here we analyze the effect of these filters on the power of exome
sequencing for RMMDs. As expected, higher filtering efficiency
(smaller m) increases the power (Figure 4). Interestingly, filtering
efficiency has a more dramatic effect for dominant models than for
recessive models. For example, reducing m from 500 to 50 for
n=200 can only improve power from 0.769 to 0.989 for a
recessive model, but can improve power from 0 to 0.692 for a
dominant model.
It is worth noting that when m is small (m,30), there is some
power for the recessive model even for a single patient n=1. This
result can be more dramatic if R is larger than the default of 0.05.
In fact, when R=1 and m=5, the power for a recessive model for
n=1 is 0.64.
There are three main strategies to reduce m. First, m can be
reduced by combining linkage information. Second, m can be
reduced by more fine-tuning of SNP filtering, fueled by the
development of public SNP databases. Finally, m can be reduced
further by applying SNP functional annotations. For example,
Figure 2. Genes underlying highly heterogeneous diseases can be identified by sequencing a moderate sized sample. The calculated
power with varying degrees of genetic heterogeneities (R) ranging from 0.01 to 1 is shown. Upper panel: power of Tr for detecting a recessive gene;
Middle panel: power difference Tr-Ta for detecting a recessive gene; Lower panel: power of Td for detecting a dominant gene. Other parameters are
fixed to the default values: number of mutations m=300; total number of genes M=20,000; sensitivity of detecting mutations Ps=0.8; and the
mutation probability equals genome-wide average w=1. See Tables S2, S3 and S4 for more dense sampling of R values. Note that power does not
always increase monotonously with sample sizes (zigzag line patterns). The loss of power upon increase of sample size is related to discrete changes
in the significance level cutoff ta of the test and thus very small test size (not close to 0.05) as shown in Table S1, since the distribution of the test
statistic is discrete.
doi:10.1371/journal.pone.0031358.g002
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frameshifts have been productive (Ng et al [3]). Moreover,
functional prediction of variants provided by programs such SIFT
[25], PolyPhen [26], and the genomic evolutionary rate profiling
(GERP) score [27] can be applied. However, these function
predictions are not yet sufficiently accurate (Ng et al [2]; Ng et al
[3]). Finally, function prediction filtering is a double-edged sword:
while it eliminates false positive by reducing m, it can also filter out
true disease-causing mutations (reducing Ps) and thus hurt the
statistical power.
Power is low for long genes
In the calculations above we assume that the probability of a
random mutation falling in a gene is equal to the genomic average
1/M. In reality the probability of a random mutation falling in a
gene may fluctuate depending on the gene size and the local
mutation rate. For convenience, we will interpret w of a gene as
the total length of its exons.
Gene size has a strong influence on power (Figure 5). Power for
long genes is low: for a recessive model with w=10 or a dominant
model with w$2, there is nearly no power at all. On the other
hand, there is a limited gain in power for shorter genes: there is not
much difference between w=0.1 and w=0.2 for both recessive
and dominant models. In practice, it should be critical to include
gene size for calculating P-values, as illustrated below.
Re-analyses of published data
We tested whether our framework can help guide both
experimental design and data analysis in recently published
exome sequencing studies [2,3]. Exome sequencing was conducted
to investigate Miller syndrome, a recessive disorder, for four
patients from three kindreds (Ng, et al. [2]). The relevant
parameters were m=526, M=17,000, Ps=0.97, and n=3. This
is a sufficiently powered design: the retrospective power calculated
with these parameters would be 0.99 (using the Tr statistic) for
discovering a gene of average length and no locus heterogeneity
(R=1). Using the actual data from this study, we estimate that w
would be 0.736 as the average length of proteins in the CCDS
2008 (20090327), the target exome capture set, is 538 aa, and the
identified gene DHODH encodes a 396 aa protein. As a result, the
calculated p-value would be 3.2610
26, more significant than the
p-value of 1.5610
25 reported (Ng, et al. [2]). Therefore, analysis
under our framework is consistent the study design and the data
analysis of Ng, et al. [2], but gives more quantitative details.
Exome sequencing is less-powered for dominant diseases. As
indicated from the model, lowering the level of false positives
Figure 3. High sensitivity of detecting mutations is required to achieve a useful power. The power for varying degrees of sensitivities of
mutation detection, ranging from 0.1 to 1 is shown. Other parameters are fixed to the default values: number of mutations m=300; total number of
genes M=20,000; genetic heterogeneity R=0.05; and the mutation probability equals genome-wide average w=1. See Tables S5 and S6 for more
dense coverage of sensitivities of mutation detection.
doi:10.1371/journal.pone.0031358.g003
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diseases. This is consistent with data presented in a study in which
exome sequencing was conducted for 10 unrelated individuals with
Kabuki syndrome, a dominant disorder (Ng et al [3]). After allele
frequency based filtering using dbSNP, 1000 Genome projects, and
control exomes, an average of 694 candidate genes per patient were
identified (Table 1 ofNg,etal.[3]).They foundthat sevenoutofthe
10 patients carry rare variants in the MLL2 gene. However, since
MLL2 is about ten times the average gene size, this observation
(Td=7) is actually not statistically significant (p=0.007 before
Bonferroni correction). When a stringent loss-of-function filter was
applied, the false positive rate is reduced by nine fold with each
individual having an average of 75 mutations. As a result, the p-
value for observing seven out 10 patients carrying rare variants in
MLL2 become 6.98610
25 and is statistical significant. Interestingly,
MUC16 wasconsideredasa ‘‘likelyfalsepositiveduetoitsextremely
large size’’ although all 10 patients carried rare mutations in this
gene (Ng, et al. [3]).Indeedouranalysisconfirmed thisclaim:dueto
the large coding region size (14,507 aa), the p-value for finding
mutations in MUC16 in 10 out of 10 patients is still not significant
even before Bonferroni correction. In other words, using p-values of
the Td statistic, MUC16 should be ranked lower than MLL2 even
though more individuals carry MUC16 mutations.
The data analysis of exome sequencing experiment can be more
challenging than merely filtering of variants using existing SNP
databases. In fact, Ng, et al. [3] developed a post hoc ranking scheme
for candidate genes. They first assign case scores to patients based
on their phenotypes and functional prediction scores to individual
variants, and then rank the candidate genes by the summation of
case scores and variant scores. A more rigorous analysis of exome
sequencing data should be undera formalstatistical framework, and
our work provides a start toward this direction.
Discussion
Exome and whole genome sequencing of patients are becoming
a major approach for unlocking the molecular basis of unchar-
acterized human rare Mendelian disease loci. In this report, we
have identified various disease and design factors that influence the
statistical power of this approach. An analytical framework that
quantitatively links these factors to statistical power has been
established. This model is validated by computational simulation.
As expected, the statistical power of identifying disease genes is
affected by both experimental conditions as well as intrinsic
features of the diseases. Importantly, based on our model, for
recessive Mendelian diseases, the vast majority of disease genes
can be readily identified when a moderate number of patients with
the same disease are sequenced and analyzed together. This is true
even when the heterogeneity of the disease is high. For example, in
the case of recessive disease, a power of 0.89 can be reached for
Figure 4. Strict filtering of false positives has limited impact on recessive diseases but dramatically reduces the power of detecting
dominant disease genes. The power for varying degrees of filtering efficiencies, ranging from 5 to 500, is shown. Upper panel: power of Tr for
recessive data; Lower panel: power of Td for dominant data. Other parameters are fixed to the default values: genetic heterogeneity R=0.05; total
number of genes M=20,000; sensitivity of detecting mutations Ps=0.8; and the mutation probability equals genome-wide average w=1. See Tables
S7 and S8 for more dense coverage of filtering efficiencies.
doi:10.1371/journal.pone.0031358.g004
Statistical Power of Exome Sequencing
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population by sequencing 200 unrelated patients. In contrast, the
powerfordominant diseasesissubstantiallylowerwheresequencing
of more than 1000 patients is needed to achieve a comparable
power. Our result is significant since it indicates that the molecular
basis for the vast majority of uncharacterized recessive disease loci
can be resolved using the exome sequencing approach.
Our framework can provide guidance for both experimental
design and data analysis. In general, proper combination of
sufficient sample size, capture sequencing coverage, cutoff for
variants identification, stringency of variants filtering, and
inclusion of genetic mapping information are important to
maximize the success of exome sequencing experiments. However,
strategies used to tackle recessive versus dominant disease are quite
different. In the case of recessive disease, the key factor is the
sample size. Based on our model, genes underlying highly
heterogeneous recessive diseases can be identified by sequencing
a moderate number of patients. In contrast, since the Tr statistic,
counting the number of individuals with $2 mutations is already
quite effective for recessive diseases, reducing false positive
mutations by aggressive allele frequency filters and bioinformatic
filtering have only a minor impact on improving power. In the
case of dominant diseases, the key factor is to reduce the number
of candidate variants. Both aggressive filters and genetic mapping
should be implemented to maximize the exclusion of variants in
order to improve the power. In contrast, although positively
correlated, increasing sample size has limited impact on the power
for highly heterogeneous dominant diseases. Other than variant
filtering and sample size, a common factor important for
experimental design is the underlying heterogeneity of the disease.
To increase power, it is highly desirable to minimize heterogene-
ity. This may be achieved by grouping patients based on their
clinical phenotype. In addition, reiterating the analysis by
excluding samples with already identified causative mutations
can also be informative. An often overlooked but potentially
confounding factor to be considered during data analysis is the
length of the gene. As genes with large size incur more rare
variants by chance, it is important to adjust the statistical
significance of findings based on gene size. To facilitate the
ranking of putative disease genes, the binomial test p-values
proposed in our report can be calculated for each candidate gene,
which provides a unified metric to rank genes similarly to what is
used in Genome-wide Association Studies (GWAS) analyses. To
facilitate experimental design, statistical power estimation, and p-
value calculation, an online calculator has been developed and can
be accessed at http://exomepower.ssg.uab.edu.
Our results show that, for rare monogenic Mendelian diseases,
it would be feasible to apply the exome-sequencing approach to
discover causative genes even when a substantial level of genetic
heterogeneity exists among patients. This can be achieved by
Figure 5. Power is low for long genes. The power for varying degrees of relative mutation probabilities, ranging from 0.1 to 10 times the genome
average is shown. Upper panel: power of Tr for recessive data; Lower panel: power of Tr for recessive data. Other parameters are fixed to the default
values: number of mutations m=300; genetic heterogeneity R=0.05; total number of genes M=20,000; and sensitivity of detecting mutations
Ps=0.8. See Tables S9 and S10 for more dense coverage of filtering efficiencies.
doi:10.1371/journal.pone.0031358.g005
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significance of identified mutations present in a small portion
of a relatively large collection. Therefore, a key to identifying
genetically heterogeneous rare Mendelian disease genes is to
collect large samples of patients and analyze the sequence data
together. As patients with mutations in individual disease genes are
rare, it will be more efficient and powerful to combine samples
with the same disease from multiple collections for sequencing. In
effect, the study of rare disease is not unlike the study of common
diseases in which investigators form large consortiums to achieve a
sufficiently powered sample size. Given a sufficient number of
samples, the lack of extended family data, a major bottleneck for
linkage-based disease gene mapping approaches, does not pose a
substantial problem for exome sequencing.
Admittedly, in this work we adopted a simple statistical
framework. Real RMMD exome data analyses often involve in
applications of a number of filters. There are several directions
where a more advanced statistical framework could be estab-
lished. First, the current framework assumes there is only a single
mutation filter. In real data analysis there is often an array of
filters, each with a different set of criteria, that are applied in
combination. It is an interesting question how to best combine
these filters and adjust the p-values accordingly. Second, the
current framework adopts simple mutation count statistics. It
may be useful to take into account the strengths of different types
of mutations and the phenotypic differences among patients,
such as the weighted sum statistics [28] and the post hoc score
developed by Ng et al [3]. Third, explicit modeling of disease
heterogeneity, either phenotypic or genetic, should be explored
as well. Fourth, the proposed test for recessive diseases simply
requires that at least two mutations are present in a same gene, as
haplotype information of these mutations are typically unavail-
able. It is possible, with improved genotype and haplotype calling
algorithms or longer sequencing reads, that haplotype informa-
tion can be estimated or observed, and thus one can improve the
recessive test by requiring two mutations to be on different
chromosomes. Fifth, mutation filters may be applied based on
allele frequencies. Our discussion was mostly focused on strict
filters which assume that disease-causing mutations are not
present in any of healthy individuals. While this is likely true for
dominant diseases and very rare recessive diseases, it may not be
true for rare recessive diseases with a moderate prevalence, in
which case mutations may be present in healthy individuals in
heterozygous state. In that case, filters based on a certain allele
frequency cutoff may be more appropriate. Sixth, software tools
predicting variants’ pathogenicity such as PolyPhen2 [26], SIFT
[25], and MutationTaster [29] are often used. The statistical
properties of these filters may be studies in future research.
Seventh, while this work is primarily focused on exome
sequencing, the main results are also applicable to the analysis
of the genic portion of whole genome sequencing for rare
diseases [15]. Finally, many successful discoveries of disease-
causing genes of RMMD by exome sequencing capitalize on the
rich information on family information. For example, rare
recessive diseases often run in highly inbred families in which
patients often carry a common homozygous mutation. While our
model is designed for exome sequencing of unrelated individuals
of rare Mendelian diseases, it offers insights into two factors that
may explain the high rate of success of familial exome
sequencing: This would be a special case with zero genetic
heterogeneity (R=1). Also, very strict filtering criteria requiring
disease causing mutations to be homozygous can be used,
resulting very small m.
Materials and Methods
Setup of the framework
An exome-sequencing study for a rare disease consists of n
unrelated patients. Suppose m mutations survive rigorous filtering,
scattered among a total of M candidate genes. For simplicity we
assume that the number of surviving mutations is the same for
each individual sequenced patients. In practice the number will
vary between individuals but the variation is likely small. The raw
data collected is an n-by-M count matrix, C, in which element Cij is
the number of mutations at gene j for individual i. Xij is the coding
of genotype at gene j for individual i. Under a recessive model,
Xr
ij~I(Cij§2), where I(x) is the indicator function taking 1 if x is
true, and 0 otherwise, and the superscript r denotes the recessive
model. Under the dominant model, Xd
ij~I(Cij§1), and the
superscript d denotes the dominant model. There is no additive
model for Mendelian diseases, but for the sake of completeness,
the genotype coding for an additive model is Xa
ij~Cij. As in most
association studies, we are interested in the statistic Tj~
P
i
Xij for
gene j, as it aggregates information across multiple patients. There
are three versions of the T-statistics, Tr, Td, and Ta, for recessive,
dominant, and additive models, respectively.
Type-I error rate and significance-level cutoff
We focus our discussion on single gene based test and consider
one gene of interest, namely, gene j, at a time. Under the null
hypothesis, gene j is not associated with the disease, and all m
mutations identified after filtering are random non-causal muta-
tions. We first assume that gene j is of average length and the
conditional probability of each of the m mutations landingon gene j,
given that there is a mutation, is p~
1
M
. This is obviously simplistic
and we will provide treatment for different gene length in later
discussion. As a result, the mutation count of gene j, given that
there are total m mutations, follows a binomial distribution:
Cij*Bin m,
1
M
  
. We remark that this is not a hypergeometric
distribution as mutations can land on the same gene multiple times.
Since we only focus on a single gene at a time and omit the subscript
jinthefollowingdiscussions.Foratypicalexomesequencingproject
for a Mendelian disease after rigorous filtering, m is much smaller
than M and thus 1{
m
M
&1. It can be shown that Xd
i for a
dominant model is a Bernoulli random variable with p&
m
M
,a n d
Xr
i for a recessive model is a Bernoulli random variable with
p&
m(m{1)
M2 and these approximations are very tight (see
DocumentS1).Therefore,the dominant-version oftheT-statisticsis
Td~
X n
i~1
Xd
i*Bin n,
m
M
  
:
Similarly, the recessive-version of the T-statistics follows
Tr~
X n
i~1
Xr
i*Bin n,
m(m{1)
M2
  
:
Moreover, the additive-version of the T-statistics is
Ta~
X n
i~1
Xa
i*Bin nm,
1
M
  
:
.
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may fluctuate depending on its size and its local background
mutation rate. Assume a gene with a probability p that is w times of
the genomic average to carry a mutation, i.e., p~
w
M
, we can use
M0~
M
w
and the above derivations still apply if we substitute M
with M9.
Based on the above derivations, an exact binomial test can be
implemented where the score cutoff ta of a test statistic T for a
given significance level a is set to be ta~min tF t ðÞ §1{a j fg ,
where F 0 ðÞis the binomial cumulative distribution function of T.
Since we are considering a total of M potential hypotheses, one for
each gene, a multiple testing correction is required. We adopt the
Bonferroni correction in the present work, where the significance
level is set to be a0~a=M. Notice that the binomial distribution is
discrete and thus for a fixed a0, the cutoff ta0 can be a stepwise
function of the sample size n. This explains the non-continuous
nature of the power curves in the Figures 2, 3, 4, and 5.
Power calculation
For a gene with a recessive link, for a patient, we assume that
there are exactly two mutations, one on each chromosome, in the
gene of interest. There is a probability R that the gene carries these
two mutations. When the gene carries the two mutations, there is a
probability Ps to discover either of them. Therefore, the
distribution of the number of mutations under a recessive model,
ci, would be a ‘‘trinomial’’ distribution:
Pr(ci~0)~
Pr(ci~1)~
Pr(ci~2)~
(1{R)zR(1{Ps)
2
2RPs(1{Ps)
RPs
2
:
The distribution of the recessive version of the T-statistic for a
recessive gene is
Tr
r~
X n
i~1
Ic i§2 ðÞ *Bin(n,RPs
2),
where the superscript r stands for recessive genetic model and the
subscript r stands for the recessive version of the T-statistic. The
distribution of the dominant version of the T-statistics for recessive
gene is:
Tr
d~
X n
i~1
Ic i§1 ðÞ *Bin n,RPs
2z2RPs 1{Ps ðÞ
  
:
The distribution of the additive version of the T-statistic
Tr
a~
P n
i~1
ci follows an extension of the binomial distribution,
which we call the ‘‘trinomial distribution’’:
Pr Tr
a~k
  
~
X n
i~0
n
i
  
n{i
k{2i
  
qipk{2i 1{p{q ðÞ
nzi{k,
where p~Pr ci~1 ðÞ ~2RPs(1{Ps), and q~Pr(ci~2)~RPs
2.
Throughout this work, we used this exact formula in our power
calculations. As a note, this distribution can be approximated by a
normal distribution when n is large, just like a binomial:
Tr
a*N 2qzp,
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p(1{p)z4q(1{p{q)
p   
.
For a gene with a dominant link, we assume that there is exactly
one mutation on our gene of interest. For a patient, there is a
probability R that the gene carries this mutation. When the gene
carries the mutation, there is a probability Ps to discover it.
Therefore, the distribution of the number of mutations under
a dominant model would be ci*Bin 1,RPs ðÞ , and the distri-
bution of the additive version of the T-statistics and the
distribution of the dominant version of the T-statistics are equal:
Td
d~Td
a ~
P n
i~1
ci§1 ðÞ ~
P n
i~1
ci*Bin(n,RPs). The recessive ver-
sion of the T-statistics Tr, however, has zero power for detecting
dominant variants.
The above discussions are focused on the contribution to the
disease from single genes. In reality there could be J disease-
causing genes g1,:::,gJ, each gj with a certain power Pj being
identified by exome sequencing. As a result, the power of
identifying any of them will be the Ptotal~1{ P
J
j~1
1{Pj
  
.
Web Resources
Online Exome Power Calculator: http://exomepower.ssg.uab.
edu
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Figure S1 The power difference of Tr-Td for recessive
data for varying degrees of genetic heterogeneities (R-
values) ranging from 0.01 to 1. Other parameters are fixed to
the default values: number of mutations m=300; total number of
genes M=20,000; sensitivity of detecting mutations Ps=0.8; and
the mutation probability equals the genome-wide average w=1.
(EPS)
Table S1 The empirical type-I error rates of Tr, Ta, and
Td by computer simulations. Different combinations of
sample sizes (n) and sensitivities of mutation detection (Ps) are
explored. In each experiment m=500 mutations are generated over
M=20,000 genes with the null distribution. The empirical type-I
error is defined as the proportion of experiments when statistics T is
greater than the cutoff determined by the Bonferroni-corrected
a~0:05 significant level (a0~2:5|10{6), over the total of 1,000
experiments. It is clear that the type-I error rates are well-controlled
in all cases (the small number of cases when the type-I error rates is
greater than 0.05 are highlighted in bold), many are even too
conservative due to the discrete nature of the binomial test.
(DOC)
Table S2 The calculated power of Tr for detecting a
recessive gene with varying degrees of genetic hetero-
geneities (R) ranging from 0.01 to 1. Other parameters are
fixed to the default values: number of mutations m=300; total
number of genes M=20,000; sensitivity of detecting mutations
Ps=0.8; and the mutation probability equals the genome-wide
average (w=1).
(DOC)
Table S3 The power difference of Tr-Ta for recessive
data for varying degrees of genetic heterogeneities (R-
values) ranging from 0.01 to 1. Negative numbers are
highlighted in bold. Other parameters are fixed to the default
values: number of mutations m=300; total number of genes
M=20,000; sensitivity of detecting mutations Ps=0.8; and the
mutation probability equals the genome-wide average w=1.
(DOC)
Table S4 The power of Td for dominant data for
varying degrees of genetic heterogeneities ranging from
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number of mutations m=300; total number of genes M=20,000;
sensitivity of detecting mutations Ps=0.8; and the mutation
probability equals the genome-wide average w=1.
(DOC)
Table S5 The power of Tr for recessive data for varying
degrees of sensitivities of mutation detection, ranging
from 0.1 to 1. Other parameters are fixed to the default values:
number of mutations m=300; total number of genes M=20,000;
genetic heterogeneity R=0.05; and the mutation probability
equals the genome-wide average w=1.
(DOC)
Table S6 The power of Td for dominant data for
varying degrees of sensitivities of mutation detection,
ranging from 0.1 to 1. Other parameters are fixed to the
default values: number of mutations m=300; total number of
genes M=20,000; genetic heterogeneity R=0.05; and the
mutation probability equals the genome-wide average w=1.
(DOC)
Table S7 The power of Tr for recessive data for varying
degrees of filtering efficiencies, ranging from 5 to 500.
Other parameters are fixed to the default values: genetic
heterogeneity R=0.05; total number of genes M=20,000;
sensitivity of detecting mutations Ps=0.8; and the mutation
probability equals the genome-wide average w=1.
(DOC)
Table S8 The power of Td for dominant data for
varying degrees of filtering efficiencies, ranging from 5
to 500. Other parameters are fixed to the default values: genetic
heterogeneity R=0.05; total number of genes M=20,000;
sensitivity of detecting mutations Ps=0.8; and the mutation
probability equals the genome-wide average w=1.
(DOC)
Table S9 The power of Tr for recessive data for varying
degrees of relative mutation probabilities, ranging from
0.1 to 10 times of the genome average. Other parameters
are fixed to the default values: number of mutations m=300;
genetic heterogeneity R=0.05; total number of genes M=20,000;
and sensitivity of detecting mutations Ps=0.8.
(DOC)
Table S10 The power of Td for dominant data for
varying degrees of relative mutation probabilities,
ranging from 0.1 to 10 times of the genome average.
Other parameters are fixed to the default values: number of
mutations m=300; genetic heterogeneity R=0.05; total number of
genes M=20,000; and sensitivity of detecting mutations Ps=0.8;
and the filtering efficiency m=300.
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